Delving into the Latest Updates on Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd. with Synapse

Overview

Tags

Other Diseases

Congenital Disorders

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

AHR(Aryl hydrocarbon receptor)	1
Opioid receptors	1

比较餐后单次给药条件下，上海新亚药业闵行有限公司生产的盐酸贝那普利片（规格：10mg，受试制剂）与MEDA Pharma GmbH & Co. KG生产的盐酸贝那普利片（规格：10mg，参比制剂）在健康受试者中吸收程度和速度的差异。通过主要药代动力学参数，评价两者是否生物等效，为受试制剂的注册申请提供依据。通过观察安全性指标，评价盐酸贝那普利片的安全性。

[Translation]

To compare the differences in absorption extent and rate of Benazepril Hydrochloride Tablets (Specification: 10 mg, test preparation) produced by Shanghai Xinya Pharmaceutical Minhang Co., Ltd. and Benazepril Hydrochloride Tablets (Specification: 10 mg, reference preparation) produced by MEDA Pharma GmbH & Co. KG in healthy subjects under the condition of single administration after meal. The main pharmacokinetic parameters were used to evaluate whether the two were bioequivalent, providing a basis for the registration application of the test preparation. The safety of Benazepril Hydrochloride Tablets was evaluated by observing safety indicators.

Start Date05 Jul 2019

Sponsor / Collaborator

Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd.

100 Clinical Results associated with Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd.

Login to view more data

1

Literatures (Medical) associated with Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd.

Zhongguo Yiyao Gongye Zazhi

Classification tree model for drug penetrability classification identification of biopharmaceutics classification system

Author: Zeng, Chuiyu ; Wang, Xiaoyan

This study identified the penetrability classification of the given compounds in biopharmaceutics classification system (BCS) through the establishment of mol. property based classification tree model.The Caco-2 cell penetration data collected from different literatures was used to constitute the training set.Classification tree model was built on the basis of the training set and applied in the classification test of the external test set, which was from the FDA BCS standard compoundsRules for the identification of BCS penetrability classification was: if the number of hydrogen bond donor was less than 4, the pos. Van der Waals polar surface area was less than 40.71 and the solvation energy was over -33.89, the compound had high penetrability, otherwise, low penetrability.The recognition correct rates of 105 compounds' training set and 17 compounds' external test set were 91.43% and 82.35%, resp.The mol. property classification modeling was successfully used in the FDA BCS standard compoundsThis study provided a convenient and feasible tool for the identification of medicinal penetrability of compounds

100 Deals associated with Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

NDA/BLA

Approved

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Loperamide Hydrochloride ( Opioid receptors )	Diarrhea More	Approved
TAP-1503 ( AHR )	Dermatitis, Atopic More	NDA/BLA
Acetic Acid, Glacial	Contraception More	Phase 2